Clascoterone vs Dianabol
FDA Approved vs Well Studied
monitor Mechanism-based · 51% Both Clascoterone and Dianabol carry androgenic activity. Additive androgenic load increases risk of acne, hair loss, and prostate effects. Monitor for dose-dependent side effects.
Molecular Data
Clascoterone Dianabol
Weight 388.54 Da 300.44 Da
Half-life Short topical (local action; rapidly metabolized to cortexolone) ~4-6 hours
Type Steroidal androgen receptor inhibitor 17-alpha-alkylated anabolic steroid (C20H28O2)
Key Benefits
Clascoterone
01 First-in-class topical androgen receptor inhibitor with FDA approval for acne
02 Blocks androgen action locally at the sebaceous gland and hair follicle without systemic hormonal effects
03 Suitable for both men and women, unlike systemic anti-androgens
04 Rapidly metabolized to inactive cortexolone, limiting systemic exposure
05 No clinically meaningful effects on systemic testosterone, DHT, or gonadotropin levels
06 Addresses the root androgen-driven pathology of both acne and androgenetic alopecia
Dianabol
01 Rapid and dramatic increases in muscle mass and bodyweight
02 Significant strength gains within the first 1-2 weeks
03 Enhanced nitrogen retention and protein synthesis
04 Improved glycogenolysis and muscular endurance
05 Pronounced muscle fullness and pumps from increased intracellular water and glycogen
06 Effective oral kickstart while waiting for injectable compounds to saturate
07 One of the fastest-acting anabolic compounds available
Side Effects
Clascoterone
Application site irritation, redness, or dryness
Pruritus (itching) at the application site
Contact dermatitis in sensitive individuals
Dianabol
Significant water retention and bloating (estrogen-mediated)
Elevated blood pressure from fluid retention and increased red blood cell mass
Liver stress with elevated ALT/AST enzymes (dose and duration dependent)
Back pumps (painful lower back cramping during exercise)
Increased appetite
Oily skin and acne
Suppression of endogenous testosterone production (HPTA suppression)
Mild mood changes (increased aggression, irritability, or euphoria)
Contraindications
Known hypersensitivity to clascoterone or any component of the formulation
Women who are pregnant or planning to become pregnant (anti-androgens carry theoretical teratogenic risk)
Women who are breastfeeding (safety not established)
Active skin infections at the intended application site
Pre-existing liver disease or impaired hepatic function
Active or history of hormone-sensitive cancers (prostate, breast)
Uncontrolled hypertension or significant cardiovascular disease
Elevated hematocrit (above 54%) at baseline
Concurrent use of other hepatotoxic oral steroids (do not stack C17-aa orals)
Pregnancy or potential exposure to pregnant women
Heavy alcohol use (compounded hepatotoxicity risk)
Cholestatic liver conditions or history of drug-induced liver injury
Research Evidence
Clascoterone Dianabol
Status FDA Approved Well Studied
References 4 studies 5 studies
Latest — 2017
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.